Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Calvert

Showing results (161-170 of 220) with videos related to

Pageof 22
Sort By:
Gynecologic Oncology|September 24, 2004
A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancerA Clamp, M Adams, R Atkinson, et al.
British Journal of Cancer|March 1, 1995
The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancerM J Lind, L Gumbrell, B M Cantwell, et al.
Journal of Medicinal Chemistry|June 1, 1986
Quinazoline antifolates inhibiting thymidylate synthase: variation of the amino acidT R Jones, M J Smithers, R F Betteridge, et al.
Journal of Medicinal Chemistry|November 1, 1990
Quinazoline antifolate thymidylate synthase inhibitors: 2'-fluoro-N10-propargyl-5,8-dideazafolic acid and derivatives with modifications in the C2 positionA L Jackman, P R Marsham, T J Thornton, et al.
Cancer Chemotherapy and Pharmacology|August 8, 2001
Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancerA V Boddy, M J Griffin, J Sludden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1995
Cancer Research Campaign phase II trial of temozolomide in metastatic melanomaN M Bleehen, E S Newlands, S M Lee, et al.
Cancer Treatment Reviews|January 1, 1993
Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic resultsA H Calvert, M J Lind, M M Millward, et al.
British Journal of Cancer|August 1, 1996
The relationship between tumour glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patientsS Ghazal-Aswad, L Hogarth, A G Hall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2000
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell linesC A Delaney, L Z Wang, S Kyle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 1995
Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusionI Rafi, G A Taylor, J A Calvete, et al.
Pageof 22

Showing results (161-170 of 220) with videos related to

Sort By:
Pageof 22
Gynecologic Oncology|September 24, 2004
A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancerA Clamp, M Adams, R Atkinson, et al.
British Journal of Cancer|March 1, 1995
The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancerM J Lind, L Gumbrell, B M Cantwell, et al.
Journal of Medicinal Chemistry|June 1, 1986
Quinazoline antifolates inhibiting thymidylate synthase: variation of the amino acidT R Jones, M J Smithers, R F Betteridge, et al.
Journal of Medicinal Chemistry|November 1, 1990
Quinazoline antifolate thymidylate synthase inhibitors: 2'-fluoro-N10-propargyl-5,8-dideazafolic acid and derivatives with modifications in the C2 positionA L Jackman, P R Marsham, T J Thornton, et al.
Cancer Chemotherapy and Pharmacology|August 8, 2001
Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancerA V Boddy, M J Griffin, J Sludden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1995
Cancer Research Campaign phase II trial of temozolomide in metastatic melanomaN M Bleehen, E S Newlands, S M Lee, et al.
Cancer Treatment Reviews|January 1, 1993
Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic resultsA H Calvert, M J Lind, M M Millward, et al.
British Journal of Cancer|August 1, 1996
The relationship between tumour glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patientsS Ghazal-Aswad, L Hogarth, A G Hall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2000
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell linesC A Delaney, L Z Wang, S Kyle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 1995
Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusionI Rafi, G A Taylor, J A Calvete, et al.
Pageof 22